Tema Etfs LLC Makes New Investment in Masimo Co. (NASDAQ:MASI)

Tema Etfs LLC acquired a new position in Masimo Co. (NASDAQ:MASI) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 9,580 shares of the medical equipment provider’s stock, valued at approximately $1,584,000.

Several other institutional investors have also added to or reduced their stakes in MASI. Jones Financial Companies Lllp bought a new position in Masimo in the 4th quarter worth $27,000. UMB Bank n.a. raised its holdings in Masimo by 180.9% in the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 123 shares in the last quarter. Trust Co. of Vermont bought a new position in Masimo in the 4th quarter worth $33,000. Blue Trust Inc. raised its holdings in Masimo by 56.3% in the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 71 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in Masimo by 40.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 64 shares in the last quarter. 85.96% of the stock is currently owned by institutional investors.

Masimo Stock Performance

Shares of MASI stock opened at $155.62 on Friday. Masimo Co. has a one year low of $101.61 and a one year high of $194.88. The company’s 50-day moving average is $160.06 and its 200 day moving average is $167.33. The company has a market capitalization of $8.44 billion, a price-to-earnings ratio of 107.32 and a beta of 1.23. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01.

Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.24 by $0.12. The firm had revenue of $372.00 million for the quarter, compared to the consensus estimate of $367.79 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business’s quarterly revenue was down 24.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.77 EPS. Sell-side analysts expect that Masimo Co. will post 4.1 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Craig B. Reynolds sold 2,053 shares of the firm’s stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $166.13, for a total value of $341,064.89. Following the transaction, the director now owns 16,581 shares of the company’s stock, valued at approximately $2,754,601.53. This trade represents a 11.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Bilal Muhsin sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $163.28, for a total transaction of $1,632,800.00. Following the completion of the transaction, the chief operating officer now directly owns 24,172 shares in the company, valued at approximately $3,946,804.16. The trade was a 29.26% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 42,053 shares of company stock valued at $6,998,565. 9.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on MASI. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research note on Thursday, April 10th. Raymond James decreased their price target on shares of Masimo from $204.00 to $185.00 and set an “outperform” rating for the company in a research note on Wednesday, May 7th. BTIG Research set a $193.00 price target on shares of Masimo and gave the stock a “buy” rating in a research note on Wednesday, May 7th. Piper Sandler reiterated an “overweight” rating and issued a $200.00 price target (down from $215.00) on shares of Masimo in a research note on Wednesday, May 7th. Finally, Wells Fargo & Company decreased their price target on shares of Masimo from $205.00 to $190.00 and set an “overweight” rating for the company in a research note on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $191.60.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.